SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Cue Biopharma, Inc. (CUE) News

Follow Cue Biopharma, Inc. (CUE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CUE Asset equity Sector Markets 90 days 7 Last 18.97 Updated Sep 21, 2026, 12:04 PM UTC Open live news feed Open CUE chart & news
M Cue Biopharma reports positive Phase 2 topline results for CUE-221 Cue Biopharma said CUE-221 met dose-responsive primary and secondary endpoints in chronic spontaneous urticaria, with a favorable safety profile and durable benefit versus placebo and omalizumab. EQUITY | Sep 21, 2026, 12:04 PM UTC M Cue Biopharma shares jump premarket on positive urticaria trial results Cue Biopharma shares rallied ahead of the opening bell after positive results in a trial of a prospective treatment for chronic spontaneous urticaria; premarket, the stock was up 51% to $56.00. EQUITY | Sep 21, 2026, 10:59 AM UTC H Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket Shares of Lobo Technologies Ltd (NASDAQ: LOBO ) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share, LIVE | Sep 21, 2026, 09:01 AM UTC L CUE - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria CUE - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria NEWS | Sep 20, 2026, 10:01 AM UTC L Cue Energy Resources posts FY revenues from operations A$50.2 million Cue Energy Resources reported FY revenues from operations of A$50.2 million. EQUITY | Aug 27, 2026, 01:24 AM UTC L Cue Biopharma reports Q2 2026 financial results, business highlights Cue Biopharma reports its second quarter 2026 financial results and recent business highlights; no financial figures, comparisons, or catalysts are provided in the feed. EARNINGS | Aug 14, 2026, 08:06 PM UTC L Multiple companies announce shelf filings and equity, debt offerings The wire lists several capital-raising actions, including ARE pricing $1,000,000,000 of Series A fixed-to-fixed reset rate junior subordinated notes due 2057 and RHP closing a common stock offering with full over-allotme MNA | Aug 13, 2026, 10:31 AM UTC M 12 Health Care Stocks Move Twelve health care stocks are moving in Tuesday's intraday session, with Aditxt and Atlantic International leading the gainers and Trinity Biotech and Tenon Medical leading the losers EQUITY | Jun 23, 2026, 05:09 PM UTC M BIVI Files $300M Mixed Shelf BIVI and other companies file mixed shelf offerings with the SEC EQUITY | Jun 22, 2026, 09:29 AM UTC